SEC Comment Letter for ALBIREO PHARMA, INC. (CIK 0001322505) — May 14, 2020
ALBIREO PHARMA, INC. (CIK 0001322505)
Date: May 14, 2020 · CIK: 0001322505 · Accession: 0000000000-20-004303
AI Filing Summary & Sentiment
File numbers found in text: 333-238063
Letter
United States securities and exchange commission logo May 14, 2020 Ronald H.W. Cooper Chief Executive Officer Albireo Pharma, Inc. 10 Post Office Square, Suite 1000 Boston, Massachusetts 02109 Re:Albireo Pharma, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238063 Dear Mr. Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Megan N. Gates, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2020
Ronald H.W. Cooper
Chief Executive Officer
Albireo Pharma, Inc.
10 Post Office Square, Suite 1000
Boston, Massachusetts 02109
Re:Albireo Pharma, Inc.
Registration Statement on Form S-3
Filed May 7, 2020
File No. 333-238063
Dear Mr. Cooper:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Megan N. Gates, Esq.